Corcept Therapeutics Incorporated (CORT)

Acerca de Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Al 3 de noviembre de 2026, la acción de Corcept Therapeutics Incorporated (CORT) subió con fuerza a $83.75, un alza de 4.10% (+$3.30) frente al cierre anterior. En la sesión, las acciones han operado entre $80.92 y $84.06. Eso ubica a CORT cerca de la mitad de su rango de 52 semanas, de $28.66 a $126.38. Corcept Therapeutics Incorporated opera en el sector de pharmaceutical preparations y tiene una capitalización de mercado de aproximadamente $8.70 mil millones, con cerca de 778.8 mil acciones negociadas.

Últimas noticias de CORT

• Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference CallYahoo Finance· 27 oct, 4:05 p.m. ET
• What Corcept Therapeutics Stock Positive Trial Results Mean For ShareholdersYahoo Finance· 26 oct, 7:31 p.m. ET
• Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian CancerYahoo Finance· 26 oct, 8:00 a.m. ET
• Can Corcept Therapeutics Stock Rally 40% After This Dip?trefis.com· 26 oct, 3:11 a.m. ET
• Genmab stock surges 9% following positive phase 3 ovarian cancer trial resultsYahoo Finance· 23 oct, 12:44 p.m. ETGMAB
• 2 cash-producing stocks to research further and 1 we find riskyYahoo Finance· 22 oct, 1:33 p.m. ET
• 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 DiabetesYahoo Finance· 20 oct, 4:00 p.m. ETEASD
• Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?Yahoo Finance· 19 oct, 8:50 a.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de CORT en un solo lugar? Crea una cuenta gratis →

• That size on the May 105s is real conviction. I like the setup only if $CORT holds above the recent base, otherwise that flow gets trapped fast. Watch how it trades into the close.

  @TopOptionsAIerts· 2 nov, 3:47 p.m. ET

• $471K bought of the $CORT May 21st $105 call 🟢

  @peloswing· 2 nov, 3:44 p.m. ET

• $CORT closed the week at $81.12 (-5.5% w/w, -5.6% Friday), below the 50-day SMA ($111.98) and above the 200-day ($74.77). RSI14 23.1. Support $80.28, resistance $122.81 (20-day range, bottom). Broad market sell-off on Friday. New hub updated: https://www.merlintrader.com/corce…

  @Merlintrader· 31 oct, 3:00 p.m. ET

• $CORT 🤓 gap or squeeze

  @moneybag888· 31 oct, 11:37 a.m. ET· Alcista

• $CORT 4th of November

  @Dimon11· 30 oct, 2:13 p.m. ET

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →